Overcoming Understaging and Undergrading in Upper Tract Urothelial Carcinoma. Comment on Ghoreifi et al. Modern Kidney-Sparing Management of Upper Tract Urothelial Carcinoma. Cancers 2023, 15, 4495
Open Access
Abstract
Kidney-sparing management for upper tract urothelial carcinoma (UTUC) has become more common but is still most limited by inaccurate histopathologic diagnosisKeywords
This publication has 7 references indexed in Scilit:
- Modern Kidney-Sparing Management of Upper Tract Urothelial CarcinomaCancers, 2023
- Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial CarcinomaJournal of Clinical Oncology, 2023
- Upper Tract Tumor En Bloc Enucleation: A Novel Approach to the Diagnosis and Management of Upper Tract Urothelial CarcinomaUrology, 2023
- Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: Systematic review and meta-analysisEuropean Journal of Surgical Oncology, 2020
- Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trialThe Lancet, 2020
- Discordance between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial CarcinomaJournal of Urology, 2018
- Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomyDrug Design, Development and Therapy, 2014